stockrow
Friday 6 November 2026
Export SGHT’s income statement to Excel — free account
Sight Sciences, Inc.
SGHT Healthcare Medical Devices
Sight Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $77.4 million, down 3.13% from fiscal 2024.
- Revenue
- +25.2%
- EPS
- +25.0%
- Free cash flow
- +72.2%
- Total debt
- +2.40%
Quarter to September 2026, against a year earlier
10.04
0.28
+2.87%
Follow SGHT
Alert me
| Sep '26 From the 10-Q filed 4 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
5.84 | 3.54 | 2.56 | 5.35 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(214.81) | (52.17) | (28.93) | (226.35) | |
P/B ratio |
10.50 | 5.59 | 3.77 | 6.47 | |
Price to Tangible BV |
10.50 | 5.59 | 3.77 | 6.47 | |
EV/Sales |
5.43 | 3.08 | 2.00 | 4.71 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(28.34) | (11.04) | (6.33) | (12.26) | |
EV/FCF |
(28.36) | (10.99) | (6.26) | (12.11) | |
Quick Ratio |
4.51 | 4.45 | 5.26 | 9.22 | |
Current Ratio |
5.04 | 4.95 | 5.86 | 10.22 | |
Net Debt/EBITDA |
6.31 | 10.98 | 3.68 | 15.52 | |
Debt/Assets |
39.09% | 38.88% | 36.95% | 34.95% | |
Debt/Equity |
0.84 | 0.77 | 0.75 | 0.63 | |
Asset Turnover |
0.80 | 0.74 | 0.66 | 0.60 | |
Operating CF/Net income |
0.35 | 1.27 | 0.54 | 0.44 | |
Capex/Depreciation |
(0.19) | (0.06) | (0.18) | 0.46 | |
Interest Coverage |
(4.67) | (3.01) | (9.79) | (2.85) | |
Research and Development Expense of Revenue |
10.86% | 10.74% | 12.93% | 11.95% | |
Selling, General and Administrative Expense of Revenue |
99.67% | 97.27% | 136.28% | 93.30% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
11.78% | 12.67% | 14.48% | 12.50% | |
Graham Net Nets |
0.09 | 0.17 | 0.25 | 0.15 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(5.56%) | (10.33%) | (18.83%) | (9.46%) | |
Free Cash Flow Yield |
(3.28%) | (7.90%) | (12.49%) | (7.27%) | |
Revenue per Share |
0.45 | 0.43 | 0.37 | 0.39 | |
Operating CF per Share |
(0.04) | (0.10) | (0.13) | (0.03) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.04) | (0.10) | (0.13) | (0.03) | |
Cash per Share |
1.40 | 1.46 | 1.58 | 1.76 | |
Shareholders Equity per Share |
0.89 | 0.97 | 1.00 | 1.23 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.89 | 0.97 | 1.00 | 1.23 | |
Free Cash Flow |
(2.47) | (5.68) | (7.09) | (1.67) | |
Working Capital |
81.33 | 80.94 | 88.35 | 101.71 | |
Capital Expenditures |
(0.07) | (0.02) | (0.06) | 0.16 | |
Net Current Asset Value |
45.66 | 49.46 | 50.71 | 61.38 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | (0.01) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
11.56 | 10.50 | 10.01 | 10.27 | |
Average Payables |
2.26 | 1.99 | 2.13 | 1.52 | |
Average Inventory |
7.24 | 5.95 | 6.41 | 7.05 | |
Average Assets |
110.60 | 113.42 | 119.69 | 129.07 | |
Average Common Equity |
56.71 | 61.45 | 65.77 | 75.73 |
Columns are period end dates · fundamentals updated 4 Nov 2026